170 related articles for article (PubMed ID: 33720083)
21. Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007.
Gao Y; Meng H; Zhang Y; Jiao T; Hui N
Int J Clin Exp Pathol; 2014; 7(4):1616-24. PubMed ID: 24817958
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study.
Wang F; Dai X; Chen H; Hu X; Wang Y
BMC Cancer; 2022 Oct; 22(1):1050. PubMed ID: 36207687
[TBL] [Abstract][Full Text] [Related]
23. A Real-World Study on Diagnosis and Treatment of Uterine Sarcoma in Western China.
Li D; Yin N; Du G; Wang S; Xiao Z; Chen J; Chen W
Int J Biol Sci; 2020; 16(3):388-395. PubMed ID: 32015676
[TBL] [Abstract][Full Text] [Related]
24. Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma.
Arita S; Kikkawa F; Kajiyama H; Shibata K; Kawai M; Mizuno K; Nagasaka T; Ino K; Nomura S
Int J Gynecol Cancer; 2005; 15(2):329-36. PubMed ID: 15823121
[TBL] [Abstract][Full Text] [Related]
25. Assessment of MR Imaging as a Tool to Differentiate between the Major Histological Types of Uterine Sarcomas.
Sumi A; Terasaki H; Sanada S; Uchida M; Tomioka Y; Kamura T; Yano H; Abe T
Magn Reson Med Sci; 2015; 14(4):295-304. PubMed ID: 26104072
[TBL] [Abstract][Full Text] [Related]
26. State of the science: Uterine sarcomas: From pathology to practice.
Shushkevich A; Thaker PH; Littell RD; Shah NA; Chiang S; Thornton K; Hensley ML; Slomovitz BM; Holcomb KM; Leitao MM; Toboni MD; Powell MA; Levine DA; Dowdy SC; Klopp A; Brown J
Gynecol Oncol; 2020 Oct; 159(1):3-7. PubMed ID: 32839026
[No Abstract] [Full Text] [Related]
27. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.
Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
Tumour Biol; 2011 Jun; 32(3):451-9. PubMed ID: 21161468
[TBL] [Abstract][Full Text] [Related]
28. Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma.
Momeni-Boroujeni A; Mohammad N; Wolber R; Yip S; Köbel M; Dickson BC; Hensley ML; Leitao MM; Antonescu CR; Benayed R; Ladanyi M; Lee CH; Chiang S
Mod Pathol; 2021 May; 34(5):1008-1016. PubMed ID: 33077922
[TBL] [Abstract][Full Text] [Related]
29. [Sarcomas and mixed mesodermal tumors of the uterus].
Günthert AR
Ther Umsch; 2011 Oct; 68(10):559-64. PubMed ID: 21968895
[TBL] [Abstract][Full Text] [Related]
30. Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma.
El Hallani S; Arora R; Lin DI; Måsbäc A; Mateoiu C; McCluggage WG; Nucci MR; Otis CN; Parkash V; Parra-Herran C; Longacre TA
Am J Surg Pathol; 2021 Mar; 45(3):374-383. PubMed ID: 33565764
[TBL] [Abstract][Full Text] [Related]
31. Role of lymphadenectomy for apparent early stage uterine sarcoma; a comprehensive analysis of the National Cancer Database.
Nasioudis D; Mastroyannis SA; Latif NA; Ko EM; Haggerty AF; Kim SH; Morgan MA; Giuntoli RL
Surg Oncol; 2021 Sep; 38():101589. PubMed ID: 33957499
[TBL] [Abstract][Full Text] [Related]
32. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms.
McCluggage WG; Sumathi VP; Maxwell P
Histopathology; 2001 Sep; 39(3):273-8. PubMed ID: 11532038
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas.
Seidman JD; Chauhan S
Int J Gynecol Pathol; 2003 Jan; 22(1):75-82. PubMed ID: 12496702
[TBL] [Abstract][Full Text] [Related]
34. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
[TBL] [Abstract][Full Text] [Related]
35. Current Status of Magnetic Resonance Imaging in Patients with Malignant Uterine Neoplasms: A Review.
Huang YT; Huang YL; Ng KK; Lin G
Korean J Radiol; 2019 Jan; 20(1):18-33. PubMed ID: 30627019
[TBL] [Abstract][Full Text] [Related]
36. Role of the Immunohistochemical ZEB1 Expression in Uterine Mesenchymal Neoplasms.
Çelik M; Çelik ZE
Int J Surg Pathol; 2022 Aug; 30(5):520-527. PubMed ID: 34994578
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis.
Huss A; Klar M; Hasanov MF; Juhasz-Böss I; Bossart M
Arch Gynecol Obstet; 2023 Mar; 307(3):927-935. PubMed ID: 35780401
[TBL] [Abstract][Full Text] [Related]
38. Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma.
Davidson B; Hellesylt E; Holth A; Danielsen HE; Skeie-Jensen T; Katz B
Virchows Arch; 2017 Sep; 471(3):355-362. PubMed ID: 28643014
[TBL] [Abstract][Full Text] [Related]
39. Uterine mesenchymal tumours: recent advances.
Momeni-Boroujeni A; Chiang S
Histopathology; 2020 Jan; 76(1):64-75. PubMed ID: 31846533
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in the treatment of sarcomas in gynecology.
Lange SS; Novetsky AP; Powell MA
Discov Med; 2014 Sep; 18(98):133-40. PubMed ID: 25227754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
